… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, the Netherlands … available on the SEC's website, located at www.sec.gov . Copies of the final prospectus supplement and the …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, Netherlands and … NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, Netherlands … are available on the SEC’s website, located at www.sec.gov . Copies of the final prospectus supplement and the …
Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor Event (virtual), featuring detailed AX-0810 P
… B4GALT1 for Cardiovascular diseases mid-2025 update on optimization for GalNAc delivery Continue to execute on … milestone income from the existing partnership, and an option to exercise for an additional five targets for … a total of 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …
… lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today … Advisory Board. As Chief ADAR Scientist, he drives the development and optimization of the Company’s Axiomer … a total of 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …
… pipeline program, QR-504a for Fuchs endothelial corneal dystrophy, is expected to advance to clinical testing in the … visual acuity, visual fields, and the objective measure of optical coherence tomography (OCT) retinal imaging, after a … The closing included the full exercise of underwriters’ option to purchase 2,076,923 additional shares. Gross …
… biomarker bile acids 72 hours after treatment. Further optimizations for EONs targeting NTCP have enabled … AX-0810 targeting NTCP for cholestatic diseases: clinical development candidate translational data to be reported, and … of deal to 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …
… AX-0810 targeting NTCP for cholestatic diseases: clinical development candidate translational data to be reported, and … milestone income from existing partnership, and potential option to exercise for expansion of deal to 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …